↓ Skip to main content

Advances in Cancer Biomarkers

Overview of attention for book
Cover of 'Advances in Cancer Biomarkers'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Cancer Biomarkers: A Status Quo
  3. Altmetric Badge
    Chapter 2 Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives
  4. Altmetric Badge
    Chapter 3 Use of Biomarkers in Screening for Cancer.
  5. Altmetric Badge
    Chapter 4 The Role of Metabolomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools
  6. Altmetric Badge
    Chapter 5 The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools.
  7. Altmetric Badge
    Chapter 6 Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development
  8. Altmetric Badge
    Chapter 7 Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects
  9. Altmetric Badge
    Chapter 8 The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects
  10. Altmetric Badge
    Chapter 9 Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects
  11. Altmetric Badge
    Chapter 10 Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer
  12. Altmetric Badge
    Chapter 11 The Role of Human Chorionic Gonadotropin as Tumor Marker: Biochemical and Clinical Aspects.
  13. Altmetric Badge
    Chapter 12 Advances in Cancer Biomarkers
  14. Altmetric Badge
    Chapter 13 Mucins and Cytokeratins as Serum Tumor Markers in Breast Cancer
  15. Altmetric Badge
    Chapter 14 The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects
  16. Altmetric Badge
    Chapter 15 CA 19-9: Biochemical and Clinical Aspects.
  17. Altmetric Badge
    Chapter 16 Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer
  18. Altmetric Badge
    Chapter 17 Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects
  19. Altmetric Badge
    Chapter 18 Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer
  20. Altmetric Badge
    Chapter 19 A Critical Approach to Clinical Biochemistry of Chromogranin A.
  21. Altmetric Badge
    Chapter 20 The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer
  22. Altmetric Badge
    Chapter 21 The Role of CTCs as Tumor Biomarkers
Attention for Chapter 12: Advances in Cancer Biomarkers
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Advances in Cancer Biomarkers
Chapter number 12
Book title
Advances in Cancer Biomarkers
Published in
Advances in experimental medicine and biology, January 2015
DOI 10.1007/978-94-017-7215-0_12
Pubmed ID
Book ISBNs
978-9-40-177214-3, 978-9-40-177215-0
Authors

Li, Dave, Satomura, Shinji, Dave Li, Shinji Satomura

Abstract

The past decades have witnessed increased use of biomarkers in disease management. A biomarker is any characteristic that can be objectively measured and evaluated as an indicator of normal biological process, pathogenic process, or pharmacological response to a therapeutic intervention. The clinical measurements of biomarkers can be carried out in vivo using imaging modalities like ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), as well as in vitro utilizing serum or plasma or other body fluids as specimens. In contrast to the imaging modalities, a prominent value of serum biomarkers is that they could be biologically relevant and disease-specific to pathophysiologic or pathologic process of disease development. This article provides an update of serum biomarkers for hepatocellular carcinoma (HCC) in risk assessment for early detection through surveillance.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 15%
Student > Ph. D. Student 4 15%
Student > Master 3 11%
Lecturer 1 4%
Librarian 1 4%
Other 2 7%
Unknown 12 44%
Readers by discipline Count As %
Medicine and Dentistry 7 26%
Biochemistry, Genetics and Molecular Biology 3 11%
Psychology 2 7%
Nursing and Health Professions 1 4%
Arts and Humanities 1 4%
Other 1 4%
Unknown 12 44%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2016.
All research outputs
#15,364,458
of 22,856,968 outputs
Outputs from Advances in experimental medicine and biology
#2,506
of 4,950 outputs
Outputs of similar age
#209,124
of 353,273 outputs
Outputs of similar age from Advances in experimental medicine and biology
#119
of 272 outputs
Altmetric has tracked 22,856,968 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,950 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,273 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 272 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.